The recommendation was based on results from two Phase III trials showing that Tevimbra plus chemo improved overall survival over chemo alone.
Avacta will tap into Tempus' real-world data and machine learning abilities to develop drugs with its fibroblast activation protein (FAP)-based platform.
The LRRK2 Investigative Therapeutics Exchange aims to advance basic sciences and support development of new drugs and LRRK2-specific biomarkers.